Abstract
Study design:
Blinded, placebo-controlled, parallel treatment group studies of the effects of methylprednisolone (MP) or 4-chloro-3-hydroxyanthranilate (4-Cl-3-HAA) on behavioral outcome and quinolinic acid tissue levels from experimental thoracic spinal cord injury in adult guinea pigs.
Objectives:
To compare the effects of treatment with high-dose MP, a corticosteroid, and 4-Cl-3-HAA, a compound that inhibits synthesis of the neurotoxin quinolinic acid (QUIN) by activated macrophages. To explore the effect of different times of treatment using these two approaches to ameliorating secondary tissue damage.
Setting:
Laboratory animal studies at the University of North Carolina, Chapel Hill, NC, USA.
Methods:
Standardized spinal cord injuries were produced in anesthetized guinea pigs, using lateral compression of the spinal cord. Behavioral impairment and recovery were measured by placing and toe-spread responses (motor function), cutaneus trunci muscle reflex receptive field areas and somatosensory-evoked potentials (sensory function). Tissue quinolinic acid levels were measured by gas chromatograph/mass spectrometry.
Results:
The current experiments showed a reduction in delayed loss of motor and sensory function in the guinea pig with MP (150 mg kg−1, intraperitoneally in split doses between 0.5 and 6 h), but no significant reduction in tissue QUIN. Improved sensory function was seen with a single dose of 60 mg kg−1 MP intraperitoneally at 5 h after injury, but not at 10 h after injury. A single dose of 4-Cl-3-HAA at 5 h in the guinea pig did not produce the sensory and motor improvements seen in previous studies with 12 days of dosing, beginning at 5 h.
Conclusion:
These studies, together with earlier findings, indicate that both drugs can attenuate secondary pathologic damage after SCI, but through separate mechanisms. These are most likely an acute reduction by MP of oxidative processes and reduction by 4-Cl-3-HAA of QUIN synthesis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Hausmann O . Post-traumatic inflammation following spinal cord injury. Spinal Cord 2003; 41: 369–378.
Blight AR, Saito K, Heyes MP . Increased levels of the excitotoxin quinolinic acid in spinal cord following contusion injury. Brain Res 1993; 632: 314–316.
Blight AR . Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. Neuroscience 1994; 60: 263–273.
Yates JR, Heyes MP, Blight AR . 4-Chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery and preserves white matter after spinal cord injury. J Neurotrauma 2006; 23: 866–881.
Hall ED . Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2001; 8: 152–167.
Young W, Flamm ES . Effect of high-dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J Neurosurg 1982; 57: 667–673.
Braughler JM, Hall ED . Lactate and pyruvate metabolism in injured cat spinal cord before and after a single large intravenous dose of methylprednisolone. J. Neurosurg 1983; 59: 256–261.
Hall ED, Springer JE . Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004; 1: 80–100.
Braughler JM, Hall ED, Means ED, Waters TR, Anderson DK . Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J Neurosurg 1987; 67: 102–105.
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. New Engl J Med 1990; 322: 1405–1411.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M et al. Administration of methylprednisolone for 24 or 48 h or tirilazad mesylate for 48 h in the treatment of acute spinal cord injury: Results of the third National Acute Spinal Cord Injury randomized controlled trial. JAMA 1997; 277: 1597–1604.
Blight AR, Cohen TI, Saito K, Heyes MP . Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain 1995; 118: 735–752.
Ozaki Y, Edelstein MP, Duch DS . The actions of interferon and antiinflammatory agents of induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun 1987; 144: 1147–1153.
Behrmann DL, Bresnahan JC, Beattie MS . Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673. Exp Neurol 1994; 126: 61–75.
Heyes MP, Quearry BJ . Quantification of kynurenic acid in cerebrospinal fluid: effects of systemic and central L-kynurenine administration. J Chromatogr 1990; 530: 108–115.
Heyes MP, Markey SP . Quantification of quinolinic acid in the rat brain, whole blood, and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic L-tryptophan administration on brain and blood quinolinic acid concentrations. Anal Biochem 1988; 174: 349–359.
Braughler JM, Hall ED . Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg 1984; 61: 290–295.
Constantini S, Young W . The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg 1994; 80: 97–111.
Bartholdi D, Schwab ME . Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res 1995; 672: 177–186.
Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, Szabo G et al. Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987; 41: 273–280.
Heyes MP, Saito K, Markey SP . Human macrophages convert L-tryptophan to the neurotoxin quinolinic acid. Biochem J 1992; 283: 633–635.
Heyes MP, Chen CY, Major EO, Saito K . Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997; 326: 351–356.
Heyes MP, Saito K, Chen CY, Proescholdt MG, Nowak TS Jr, Li J et al. Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation. J Neurochem 1997; 69: 1519–1529.
Karlik SJ, Stavraky RT, Hall ED . Comparison of tirilazad mesylate (U-74006F) and methylprednisolone sodium succinate treatments in experimental allergic encephalomyelitis in the guinea pig. Mult Scler 1996; 1: 228–235.
Blight AR, Leroy EC, Heyes MP . Quinolinic acid accumulation in injured spinal cord: time course, distribution and species differences between rat and guinea pig. J Neurotrauma 1997; 14: 89–98.
Blight AR, McGinnis ME, Borgens RB . Cutaneus trunci muscle reflex of the guinea pig. J Comp Neurol 1990; 296: 614–633.
Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP . Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 1996; 320: 595–597.
Saito K, Seishima M, Noma A, Suyama K, Markey SP, Heyes MP . 4-Chloro-3-hyrdoxyanthranilate attenuates quinolinic acid accumulation in brain following transient cerebral ischemia in the gerbil. Adv Exp Med Biol 1996; 398: 407–411.
Acknowledgements
This work was supported in part by Grant NS-33687 from NIH, NINDS, by Grant 1793 from the Spinal Cord Research Foundation of the Paralyzed Veterans of America and by research contract BA2-9701 from the American Paralysis Association.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yates, J., Gay, E., Heyes, M. et al. Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms. Spinal Cord 52, 662–666 (2014). https://doi.org/10.1038/sc.2014.118
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2014.118
This article is cited by
-
On the benefits of the tryptophan metabolite 3-hydroxyanthranilic acid in Caenorhabditis elegans and mouse aging
Nature Communications (2023)
